Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 1:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 182 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Benign Prostatic Hypertrophy (BPH) Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain

NCT05803096
View directory record Official record
Conditions
Prostate Disease, Malignancy, Benign Prostatic Hyperplasia, Prostate Cancer, Prostate Adenocarcinoma, Anxiety and Fear, Pain
Interventions
Self-Administered Nitrous Oxide, Oxygen
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 85 Years · Male only
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 11, 2026, 1:39 PM EDT
Active, not recruiting Not applicable Interventional

PRCT001 Aquablation theraPy Outcomes in pRostate Cancer patienTs

NCT06051942
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Localized Prostate Cancer
Interventions
Robotic Waterjet Treatment
Device
Lead sponsor
PROCEPT BioRobotics
Industry
Eligibility
Up to 80 Years · Male only
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
La Mesa, California • Glenview, Illinois • Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 11, 2026, 1:39 PM EDT
Terminated No phase listed Observational

IIT-2022-Simultaneous Urolift™ and Median Lobe Enucleation

NCT06157164
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift™ System and Holmium Laser Enucleation of the Prostate (HoLEP)
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
45 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 11, 2026, 1:39 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

NCT04987892
View directory record Official record
Conditions
BPH
Interventions
UroLift System, Tamsulosin Hydrochloride
Device · Drug
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
45 Years and older · Male only
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Medical Therapy of Prostatic Symptoms

NCT00021814
View directory record Official record
Conditions
Prostatic Hyperplasia, Prostatic Hypertrophy, Benign
Interventions
Doxazosin, Finasteride, Doxazosin placebo, Finasteride placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
3,407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2001
U.S. locations
17
States / cities
La Jolla, California • Aurora, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 11, 2026, 1:39 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Utilization of a Web-Based Application to Improve Patient Health Literacy and Reduce Clinic Visit Times in Holmium Laser Enucleation of the Prostate (HoLEP) Procedures and Kidney Stone Surgery

NCT07580391
View directory record Official record
Conditions
Kidney Stone, Benign Prostatic Hyperplasia
Interventions
WellPrept, Standard Care
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 100 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Phase 4 Interventional Results available

Tranexamic Acid to Improve Same-day Discharge Rates After Holmium Laser Enucleation of the Prostate (HoLEP)

NCT05082142
View directory record Official record
Conditions
Kidney Calculi, Urologic Diseases, Benign Prostatic Hypertrophy
Interventions
Tranexamic acid
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 89 Years · Male only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Not applicable Interventional Results available

Prostate Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia

NCT03055624
View directory record Official record
Conditions
Prostatic Hyperplasia, Benign, Enlarged Prostate With Lower Urinary Tract Symptoms
Interventions
Embosphere microparticles for prostate artery embolization
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 11, 2026, 1:39 PM EDT
Recruiting Phase 2 Interventional

Effects of TNF Blockade on Human BPH/LUTS

NCT06062875
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH)
Interventions
Adalimumab
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
45 Years to 80 Years · Male only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Glenview, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 11, 2026, 1:39 PM EDT
Not yet recruiting No phase listed Observational

Modified SOLTIVE Study

NCT07838077
View directory record Official record
Conditions
Calculi, Renal, Calculi, Urinary, Benign Prostatic Hyperplasia
Interventions
SOLTIVE Premium SuperPulsed Laser System
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 11, 2026, 1:39 PM EDT
Recruiting No phase listed Observational

Customized TULSA-PRO Ablation Registry

NCT05001477
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Benign Prostatic Hyperplasia
Interventions
TULSA Procedure
Device
Lead sponsor
Profound Medical Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2061
U.S. locations
5
States / cities
West Hills, California • Jacksonville, Florida • York, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Phase 3 Interventional

Phase 3 Evaluation of Re-Injection of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH)

NCT01438775
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
NX-1207
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years and older · Male only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
28
States / cities
Huntsville, Alabama • Atherton, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2014 · Synced Oct 11, 2026, 1:39 PM EDT
Terminated Phase 2 Interventional Results available

A Study in Men With Benign Prostatic Hyperplasia

NCT01097707
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
LY500307, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
40
States / cities
Huntsville, Alabama • Anchorage, Alaska • Glendora, California + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Oct 11, 2026, 1:39 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Emsella for Reducing tSUI After HOLEP

NCT07580404
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms, Enlarged Prostate (BPH)
Interventions
Emsella chair
Device
Lead sponsor
Northwestern University
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Not applicable Interventional

Robust Evaluation to Measure Improvements in Nonadherence From Low-cost Devices

NCT02015806
View directory record Official record
Conditions
Cardiovascular Disease, Diabetes, Breast Cancer, Depression, Mental Health Disorder, Prostatic Hypertrophy, Benign, Parkinson's Disease, Epilepsy
Interventions
RxTimerCap, Take-N-Slide, Pillbox
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 64 Years
Enrollment
53,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Woonsocket, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Phase 4 Interventional Results available

Deprescribing Tamsulosin in Older Men

NCT05415748
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Tamsulosin, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
55 Years to 80 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 11, 2026, 1:39 PM EDT
Completed No phase listed Observational

Brain Imaging in Men With Lower Urinary Tract Symptoms

NCT03991429
View directory record Official record
Conditions
Voiding Disorders
Interventions
Simultaneous functional MRI and urodynamic studies, Questionnaires, Post Void Residual (PVR), Uroflow and Bladder Diary, Urinalysis
Diagnostic Test · Behavioral · Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
45 Years to 90 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Oct 11, 2026, 1:39 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Laser Enucleation of Prostate (LEP) Versus Transurethral Resection of Prostate (TURP)

NCT03062111
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
ProTouch Laser Enucleation of Prostate (LEP), Transurethral Resection of Prostate (TURP)
Procedure
Lead sponsor
Boston University
Other
Eligibility
50 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Phase 2 Interventional Results available

A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)

NCT00947882
View directory record Official record
Conditions
Lower Urinary Tract Symptoms (LUTS)
Interventions
Placebo, Degarelix 10 mg, Degarelix 20 mg, Degarelix 30 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
50 Years and older · Male only
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
15
States / cities
Homewood, Alabama • Mobile, Alabama • Newport Beach, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2015 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Phase 2 Interventional

Study to Determine Safety and Effectiveness of Tadalafil on Prostate Related Sex Organ/Urinary Tract Problems

NCT00547625
View directory record Official record
Conditions
Prostatic Hyperplasia, Prostate
Interventions
tadalafil, placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
45 Years and older · Male only
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 22, 2007 · Synced Oct 11, 2026, 1:39 PM EDT
Terminated Phase 3 Interventional

Minimally Invasive Surgical Therapy for BPH

NCT00064649
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation (TUNA) Therapy, Finasteride and Alfuzosin
Device · Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
50 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
7
States / cities
Denver, Colorado • Chicago, Illinois • Rochester, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2010 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of NX-1207 for the Treatment of Benign Prostatic Hyperplasia (BPH) (Enlarged Prostate)

NCT00759135
View directory record Official record
Conditions
Benign Prostatic Hyperplasia (BPH), Enlarged Prostate
Interventions
2.5 mg NX-1207, 0.125 mg NX-1207, finasteride
Drug
Lead sponsor
Nymox Corporation
Industry
Eligibility
45 Years to 75 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
30
States / cities
Huntsville, Alabama • Tucson, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 11, 2026, 1:39 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Evaluating the Effect of Botulinum Toxin Type A on Semen Quality in Patients With Benign Prostatic Hyperplasia

NCT00894517
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
Botulinum Toxin Type A, Placebo (saline)
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
45 Years to 70 Years · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 11, 2026, 1:39 PM EDT
Withdrawn Early Phase 1 Interventional

BOTOX in Men With Prostate Cancer With Lower Urinary Tract Symptoms(LUTS)/Benign Prostatic Hyperplasia (BPH)

NCT01520441
View directory record Official record
Conditions
Prostate Cancer, Benign Prostatic Hyperplasia, Enlarged Prostate With Lower Urinary Tract Symptoms (LUTS)
Interventions
BOTOX
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
50 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 11, 2026, 1:39 PM EDT